|
Contents
|
|
|
|
Glioblastoma |
|
|
|
|
di
Tomaso E, Snuderl M, Kamoun WS, Duda DG, Auluck PK, Fazlollahi L, Andronesi
OC, Frosch MP, Wen PY, Plotkin SR, Hedley-Whyte ET, Sorensen AG, Batchelor
TT, Jain RK.
Glioblastoma recurrence after cediranib therapy in patients: lack of "rebound"
revascularization as mode of escape.
Cancer Res. 2011 Jan 1;71(1):19-28.
.JPG) Abstract |
.png)
Reprint |
.gif)
Related articles
|
|
|
Hainsworth
JD, Ervin T, Friedman E, Priego V, Murphy PB, Clark BL, Lamar RE
Concurrent radiotherapy and temozolomide followed by temozolomide and
sorafenib in the first-line treatment of patients with glioblastoma
multiforme
Cancer. 2010 May 11;. [Epub ahead of print]
Abstract
|
|
|
Glioma
(High-Grade) |
|
|
|
|
Reardon DA, Vredenburgh JJ, Coan A, Desjardins A, Peters KB, Gururangan S,
Sathornsumetee S, Rich JN, Herndon JE, Friedman HS.
Phase
I study of sunitinib and irinotecan for patients with recurrent malignant
glioma.
J Neurooncol.
2011 Jul 9. [Epub ahead of print]
Abstract |
Related articles
|
|
|
Reardon DA, Egorin MJ, Desjardins A, Vredenburgh
JJ, Beumer JH, Lagattuta TF, Gururangan S, Herndon JE 2nd, Salvado AJ,
Friedman HS
Phase I pharmacokinetic study of the vascular endothelial growth factor
receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and
hydroxyurea for malignant glioma
Cancer. 2009 Feb 26;. [Epub ahead of print]
Abstract
|
|
|
Medulloblastoma |
|
|
|
|
Meco
D, Servidei T, Zannoni GF, Martinelli E, Prisco MG, de Waure C, Riccardi R.
Dual Inhibitor AEE788 Reduces Tumor Growth in Preclinical Models of
Medulloblastoma.
Transl Oncol. 2010 Oct 1;3(5):326-35.
Abstract |
Reprint |
Related articles
|
|
|
|
